Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 15/20 | 0.85 |
| ▸ | PLA2G1B | P04054 | 9/20 | 0.65 |
| ▸ | PLA2G10 | O15496 | 4/20 | 0.65 |
| ▸ | PLA2G5 | P39877 | 3/20 | 0.65 |
| ▸ | PLA2G2F | Q9BZM2 | 3/20 | 0.57 |
| ▸ | PLA2G2E | Q9NZK7 | 3/20 | 0.57 |
| ▸ | PLA2G2D | Q9UNK4 | 3/20 | 0.57 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.57 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.57 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.57 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.57 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL820017 | 0.93 | PLA2G2A (0.84) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2F | |
| SCHEMBL818465 | 0.92 | PLA2G2A (1.00) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2F | |
| SCHEMBL818069 | 0.87 | PLA2G2A (0.84) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL818498 | 0.84 | PLA2G2A (1.00) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2F | |
| SCHEMBL2156834 | 0.83 | PLA2G2A (0.84) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL8502688 | 0.83 | PLA2G2A (0.69) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2F | |
| Varespladib Methyl SCHEMBL25678 | 0.82 | PLA2G2A (0.83) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2F | |
| Varespladib Methyl SCHEMBL29378302 | 0.82 | PLA2G2A (0.83) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2F | |
| SCHEMBL818605 | 0.81 | PLA2G2A (0.59) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2E | |
| SCHEMBL8504081 | 0.81 | PLA2G2A (0.70) | PLA2G2APLA2G1BPLA2G10PLA2G5PLA2G2F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5919810-A | SEPTIC SHOCK | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | claimed |
| US-20110301202-A1 | SPLA2 INHIBITOR CONJUGATE COMPOUNDS AND METHODS OF USE | ANTHERA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
| US-20110269786-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME IN DIABETIC PATIENTS USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. | 2011-11-03 | — | — | US | disclosed |
| WO-2011137390-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME IN DIABETIC PATIENTS USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| US-8048880-B2 | Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies | ANTHERA PHARMACEUTICALS, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20110207710-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
| EP-2341045-A1 | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid (acyloxy)alkyl or ((alkoxycarbonyl)oxy)alkyl ester as SPLA2 inhibitor | Eli Lilly and Company (US) | 2011-07-06 | — | — | EP | disclosed |
| US-20100204249-A1 | SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR AND NIACIN DRUG COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA | ANTHERA PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100160361-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. | 2010-06-24 | — | — | US | disclosed |
| US-20090131396-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. | 2009-05-21 | — | — | US | disclosed |
| US-6433001-B1 | SEPTIC SHOCK, ALLERGIC RHINITIS, RHEUMATIC ARTHRITIS, ADULT RESPIRATORY DISTRESS SYNDROME, BRONCHIAL ASTHMA, TRAUMA, AND PANCREATITIS TREATMENT | ELI LILLY AND COMPANY | 2002-08-13 | — | — | US | disclosed |
| EP-0675110-B1 | 1H-Indole-3-glyoxylamide sPLA2 inhibitors | LILLY CO ELI (US) | 2002-07-10 | — | — | EP | disclosed |
| EP-1197484-A2 | 1H-Indole-3-glyoxylamide sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2002-04-17 | — | — | EP | disclosed |
| EP-1081135-A2 | 1H-indole-3-glyoxylamide spla2 inhibitors | ELI LILLY AND COMPANY (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6175021-B1 | HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2 (SPLA2); INHIBITS RELEASE OF ARACHIDONIC ACID TO TREAT SEPTIC SHOCK; ((3-(2-AMINO-1,2-DIOXOETHYL)-2-METHYL-1-(PHENYLMETHYL)-1H-INDOL-4 -YL)OXYLACETIC ACID, FOR EXAMPLE | ELI LILLY AND COMPANY | 2001-01-16 | — | — | US | disclosed |
| US-5919943-A | INHIBITION OF SPLA2 | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | disclosed |
| US-5919810-A | SEPTIC SHOCK | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | disclosed |
| US-5733923-A | SECRETORY PANCREATIC PHOSPHOLIPASE A2 | ELI LILLY AND COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| US-5654326-A | SEPTIC SHOCK; HUMAN NONPANCREATIC SECRETORY PHOSPHOLIPASE | ELI LILLY AND COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0675110-A1 | 1H-Indole-3-glyoxylamide sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1995-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269786-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME IN DIABETIC PATIENTS USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | PLAA, PLA2G12A, PLAAT2 | PLA2G2A 15/4885PLA2G1B 12/4885PLA2G10 19/4885 |
| US-20100160361-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | PLA2G12A, PLAA, PLA2G3 | PLA2G2A 11/4885PLA2G1B 8/4885PLA2G10 18/4885 |
| US-20110207710-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | PLA2G12A, PLA2G3, PCSK9 | PLA2G2A 23/4885PLA2G1B 16/4885PLA2G10 10/4885 |
| US-20110301202-A1 | SPLA2 INHIBITOR CONJUGATE COMPOUNDS AND METHODS OF USE | PCSK9, PCSK6, NAPRT | PLA2G2A 47/4885PLA2G1B 19/4885PLA2G10 74/4885 |
| US-20100204249-A1 | SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR AND NIACIN DRUG COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA | PLA2G12A, PLA2G3, PLA2G2E | PLA2G2A 13/4885PLA2G1B 6/4885PLA2G10 12/4885 |
| US-20090131396-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | PLA2G12A, PLA2G3, PCSK9 | PLA2G2A 23/4885PLA2G1B 16/4885PLA2G10 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.